Literature DB >> 21045048

Why the FDA can't protect the public.

Jeanne Lenzer1, Shannon Brownlee.   

Abstract

Mesh:

Year:  2010        PMID: 21045048     DOI: 10.1136/bmj.c4753

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

Review 1.  Postmarketing surveillance for "modified-risk" tobacco products.

Authors:  Richard J O'Connor
Journal:  Nicotine Tob Res       Date:  2011-01-20       Impact factor: 4.244

2.  Medical device postapproval safety monitoring: where does the United States stand?

Authors:  Prashant V Rajan; Daniel B Kramer; Aaron S Kesselheim
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-01-06

3.  FDA regulation of cardiovascular devices and opportunities for improvement.

Authors:  Sanket S Dhruva; Rita F Redberg
Journal:  J Interv Card Electrophysiol       Date:  2012-12-21       Impact factor: 1.900

4.  Improving medical device regulation: the United States and Europe in perspective.

Authors:  Corinna Sorenson; Michael Drummond
Journal:  Milbank Q       Date:  2014-03       Impact factor: 4.911

Review 5.  Post-market surveillance to detect adverse events associated with Melody® valve implantation.

Authors:  Kevin D Hill; Bryan H Goldstein; Michael J Angtuaco; Patricia Y Chu; Gregory A Fleming
Journal:  Cardiol Young       Date:  2016-11-10       Impact factor: 1.093

6.  Medical-device recalls in the UK and the device-regulation process: retrospective review of safety notices and alerts.

Authors:  C Heneghan; M Thompson; M Billingsley; D Cohen
Journal:  BMJ Open       Date:  2011-05-15       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.